3,4-dimethoxyphenethylamine modulators of l-type calcium channel
AssigneeAuspex Pharmaceuticals, Inc.
InventorsThomas G. Gant, Sepehr Sarshar
Life of this patent
Estimating the term…
Abstract
The present invention relates to new 3,4-dimethoxyphenethylamine modulators of L-type calcium channel activity, pharmaceutical compositions thereof, and methods of use thereof.
Claims48
A compound of structural Formula I
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R37 are independently selected from the group consisting of hydrogen and deuterium;
- R38 is selected from the group consisting of hydrogen, deuterium, —OCH3, —OCH2D, —OCHD2, and —OCD3;
- at least one of R1-R38 is deuterium or contains deuterium;
- if R12-R13 are each deuterium, then at least one of R1-R11 and R14-R37 is deuterium, or R38 is deuterium, —OCH3, —OCH2D, —OCHD2, or —OCD3;
- if R14-R16 are each deuterium, then at least one of R1-R13 and R17-R37 is deuterium, or R38 is deuterium, —OCH3, —OCH2D, —OCHD2, or —OCD3;
- if R12-R16 are each deuterium, then at least one of R1-R11 and R17-R37 is deuterium, or R38 is deuterium, —OCH3, —OCH2D, —OCHD2, or —OCD3;
- if R7-R9, R30-R31, and R38 are each deuterium, then at least one of R1-R6 , R10-R29, and R32-R37 is deuterium;
- if R23-R29 are each deuterium, then at least one of R1-R22 and R29-R37 is deuterium, or R38 is deuterium, —OCH3, —OCH2D, —OCHD2, or —OCD3;
- and
- if R7-R9 and R30-R31 are each deuterium, and R38 is —OCH3, then at least one of R1-R6 , R10-R29, and R32-R37 is deuterium.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R37 are independently selected from the group consisting of hydrogen and deuterium;
- R38 is selected from the group consisting of hydrogen, deuterium, —OCH3, —OCH2D, —OCHD2, and —OCD3;
- and
- at least one of R1-R38 is deuterium or contains deuterium.
A method of treatment of a L-type calcium channel-mediated disorder comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound of structural Formula I
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R37 are independently selected from the group consisting of hydrogen and deuterium;
- R38 is selected from the group consisting of hydrogen, deuterium, —OCH3, —OCH2D, —OCHD2, and —OCD3;
- and
- at least one of R1-R38 is deuterium or contains deuterium.
A compound for use as a medicament, said compound having structural Formula I
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R37 are independently selected from the group consisting of hydrogen and deuterium;
- R38 is selected from the group consisting of hydrogen, deuterium, —OCH3, —OCH2D, —OCHD2, and —OCD3;
- and
- at least one of R1-R38 is deuterium or contains deuterium.
A compound for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by modulating L-type calcium channel activity, said compound having structural Formula I
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R37 are independently selected from the group consisting of hydrogen and deuterium;
- R38 is selected from the group consisting of hydrogen, deuterium, —OCH3, —OCH2D, —OCHD2, and —OCD3;
- and
- at least one of R1-R38 is deuterium or contains deuterium.
Dependencies are inferred from the claim text.